About Us

The patented iAssay® System is a handheld medical test reader. It is agnostic to test type, and features an expandable test menu for testing patients at point of care using a fingerstick blood sample or urine sample.  Flexibility by design enables tests for cardiology, hematology, OB/GYN, infectious diseases, oncology patient,  drugs of abuse, and now also supports COVID-19 diagnostic tests. One of the key features of the iAssay device is that test results are automatically transmitted to The Cloud for remote monitoring and reuse of the data.  In September 2020, the U.S. Department of Health and Human Services (HHS) mandated that every COVID-19 test result (Positive/Negative) must be sent to the agency or risk a $500 per day fine for violations.  iAssay helps end-users comply with this mandate because data transmission is already a part of the system’s essential  functionality. iAssay lowers geophysical barriers for patient triage and medical diagnosis, increasing efficiency, convenience, and improving overall healthcare workflow.   iAssay will work with test manufacturers as the “reader” partner under an Emergency Use Authorization (EUA). The iAssay business model for COVID-19 is a reagent rental program, through which devices are placed at no-charge in return for a negotiated “Click” commission for each patient test.  Established sales channels such as independent distributors, Henry Schein and Cardinal Health, who already sell the tests read by iAssay’s device will be responsible for placing iAssay devices with their customer base.  

In the September 2020 issue of Cell, Dr. David M. Morens and Dr. Anthony S. Fauci shared their perspective on emerging pandemic diseases. They posited that “we have entered a pandemic era.”  1 The world’s most recent and most compelling daily health focus is COVID-19.  Diagnostics companies are rushing to develop accurate and reliable tests to quickly identify individuals exposed to and infected with the COVID-19 virus. The world has experienced pandemics in the past such as Spanish Flu, Swine Flu, Ebola, Zika, and now COVID-19, and the medical community predicts periodic pandemics in the future.  The iAssay device was developed to evolve just as quickly as the pathogens that it detects. There is an urgent need for accurate and reliable tests that can be easily administered by people with minimal training and that can transmit data safely and compliantly to government agencies, companies, and healthcare facilities not just for COVID-19, but for other current and future major health threats as well.

Today, iAssay provides the automated diagnostic and epidemiological tool for today’s battle with COVID-19.  The company will continue to evolve its products to provide efficient testing and Health IT capabilities not just for pandemics, but for testing to support the treatment of Chronic Diseases (costing $1.5B annually in the U.S.).

1.  Morens, D.M., Fauci, A.S., Emerging Pandemic Diseases: How We Got ToCOVID-19,Cell(2020), doi: https://doi.org/10.1016/j.cell.2020.08.021.

Join us in a live demo of the Cyber Reader
reading & recording a test cartridge.

Meeting ID: 827 5200 9942

Passcode: LaJolla

Wednesday, October 14th

5:00 PM PDT - 7:00 PM PDT 

Direct inquires to:

Lonnie Adelman, CEO/Founder
info@iassay.net    

iAssay, Inc.
9921 Carmel Mountain Rd.
Suite 777
San Diego, CA 92129